Stockreport

Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF NEW YORK and MELBOURNE, Australia, June 24, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory di [Read more]